Keyin biology obtained tens of millions of yuan in round a financing to promote the research and development of new drugs in the field of tumor metabolism with the first principle

Yiouda health news on August 26. Recently, Suzhou keyin Biomedical Technology Co., Ltd. (keyin Biology), which is committed to using AI technology to enable new drug research and development, completed tens of millions of yuan of round a financing, led by Sherpa investment and followed by angel round investor Fengrui capital. The current round of financing of the company will be used to improve the drug discovery platform and promote projects in the pipeline. Since its establishment, Coyne biology has rapidly built an ab initio drug design platform based on the first principle, which can systematically explore the whole chemical space and enhance the virtual discovery ability for new targets. By efficiently integrating upstream and downstream partners, the team gave full play to the synergy of internal and external R & D, greatly improved the cycle efficiency of DMTA and reduced the trial and error cost and cycle. Based on the iterative optimization capability of the discovery platform, the company has made significant progress in multiple early targets in the field of tumor metabolism in less than a year. The founding team of the company graduated from Harvard University, Cambridge University, Peking University, Chinese Academy of Sciences and other top universities and research institutes at home and abroad. It has rich industrial experience and has accumulated for many years in the cross fields of chemical biology, biophysics, computational chemistry and artificial intelligence. The team focuses on the field of tumor and immunity, fails to meet clinical needs, focuses on early targets with transformation advantages, and strives to provide patients with the world's first small molecule drugs in the shortest time. At the beginning of its establishment, the company has received attention from major pharmaceutical enterprises around the world and has become the first settled enterprise of Roche China accelerator.